Provided by Tiger Trade Technology Pte. Ltd.

AxoGen

37.39
-2.5300-6.34%
Post-market: 37.390.00000.00%19:30 EDT
Volume:3.10M
Turnover:117.38M
Market Cap:2.19B
PE:-55.20
High:39.92
Open:39.92
Low:36.97
Close:39.92
52wk High:52.91
52wk Low:15.27
Shares:58.67M
Float Shares:58.19M
Volume Ratio:2.50
T/O Rate:5.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6773
EPS(LYR):-0.3410
ROE:-18.21%
ROA:-3.15%
PB:8.56
PE(LYR):-109.65

Loading ...

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), AxoGen (AXGN) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 06

Will Axogen’s (AXGN) Russell Index Removal Reshape Its Liquidity Profile and Risk‑Reward Narrative?

Simply Wall St.
·
Jun 29

AxoGen Shareholders Approve Directors, Auditor and Executive Pay

TIPRANKS
·
Jun 24

Axogen shareholders elected eight directors at annual meeting

Reuters
·
Jun 24

AxoGen’s New Head-to-Head Nerve Repair Study Puts Avance Graft Under the Spotlight

TIPRANKS
·
Jun 19

AxoGen Director Makes Notable Insider Move With Fresh Stock Sale

TIPRANKS
·
May 13

Axogen director Amy McBride-Wendell disposes 1,647 shares worth $70,162.2

Reuters
·
May 13

AxoGen Insiders Quietly Unload a Wave of Shares in Major Cash-Out Spree

TIPRANKS
·
May 09

Axogen director John Johnson disposes of 11,050 shares worth $478,966.75

Reuters
·
May 09

Axogen director Kathy Johnson Weiler disposes 16,344 shares for $720,448.7

Reuters
·
May 09

Axogen CMO Jens Kemp disposes 4,000 shares worth $173,761.20

Reuters
·
May 09

Axogen CFO Lindsey Hartley disposes 1,051 shares worth $45,882.17

Reuters
·
May 09

Axogen files Form 3 showing Sales VP Doris Quackenbush beneficial ownership

Reuters
·
May 09

Stock Track | AxoGen Soars 5.13% in Pre-market on Raised 2026 Revenue Outlook and Analyst Buy Rating

Stock Track
·
May 04

Canaccord Genuity Sticks to Its Buy Rating for AxoGen (AXGN)

TIPRANKS
·
May 04

Axogen (AXGN) Is Up 10.3% After Raising 2026 Revenue Outlook Despite Wider Q1 Loss – Has The Bull Case Changed?

Simply Wall St.
·
May 04

TELA Bio Inc - Prelim Q1 2026 Revenue Approx $19.0 Mln Versus Guidance of $18.5 Mln

THOMSON REUTERS
·
May 01

TELA Bio Inc - Joseph Capper to Be Nominated as Director and Expected to Serve as Chair

THOMSON REUTERS
·
May 01

TELA Bio Inc - Chairman Doug Evans, Kurt Azarbarzin, Vince Burgess, Federica O’brien to Depart Board

THOMSON REUTERS
·
May 01

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (NAGE)

TIPRANKS
·
Apr 30